Homeobox transcription factor ventx regulates differentiation and maturation of human dendritic cells

Abstract

The invention relates to human homeobox transcription factor VentX and its regulation of differentiation and maturation of human dendritic cells, and related therapeutic and diagnostic compositions and methods of use.

1 . A method for regulating dendritic cells, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an biological or chemical agent that exerts a modulating effect of human homeobox gene VentX. 
     
     
         2 . The method of  claim 1 , wherein regulating dendritic cells comprises affecting a maturation response of dendritic cells. 
     
     
         3 . The method of  claim 1 , wherein the biological or chemical agent that exerts an inhibitory effect of human homeobox gene VentX. 
     
     
         4 . The method of  claim 1 , wherein the biological or chemical agent is a polypeptide. 
     
     
         5 . The method of  claim 1 , wherein the biological or chemical agent comprises a VentX mutant lacking the homeodomain as a blocking polypeptide. 
     
     
         6 . The method of  claim 1 , wherein the biological or chemical agent is an antibody fragment. 
     
     
         7 . The method of  claim 1 , wherein the biological or chemical agent is an oligonucleotide. 
     
     
         8 . The method of  claim 7 , wherein the oligonucleotide is an RNAi. 
     
     
         9 - 12 . (canceled) 
     
     
         13 . A pharmaceutical composition comprising a biological or chemical agent that exerts a regulatory effect on dendritic cells via a modulating effect of human homeobox gene VentX. 
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein the modulating effect comprises an inhibiting effect relevant in treatment of an inflammatory condition. 
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein the inflammatory condition is an autoimmnune disease. 
     
     
         16 . The pharmaceutical composition of  claim 13 , wherein the biological or chemical agent is a polypeptide. 
     
     
         17 . The pharmaceutical composition of  claim 13 , wherein the biological or chemical agent is an antibody. 
     
     
         18 . The pharmaceutical composition of  claim 13 , wherein the biological or chemical agent is an oligonucleotide. 
     
     
         19 - 20 . (canceled) 
     
     
         21 . A method for suppressing a tumor, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an biological or chemical agent that exerts a modulating effect on dendritic cells function. 
     
     
         22 . The method of  claim 21 , wherein the modulating effect on dendritic cells function comprises a modulating effect via human homeobox gene VentX. 
     
     
         23 . The method of  claim 22 , wherein the biological or chemical agent is a polypeptide. 
     
     
         24 . The method of  claim 22 , wherein the biological or chemical agent is an antibody fragment. 
     
     
         25 . The method of  claim 22 , wherein the biological or chemical agent is an oligonucleotide. 
     
     
         26 . The method of  claim 25 , wherein the oligonucleotide is an RNAi.